TY - JOUR T1 - Is asthma a risk factor for COVID-19? Are phenotypes important? JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00216-2020 SP - 00216-2020 AU - Xavier Muñoz AU - Florencia Pilia AU - Iñigo Ojanguren AU - C. Romero-Mesones AU - María-Jesús Cruz Y1 - 2020/01/01 UR - http://openres.ersjournals.com/content/early/2020/10/29/23120541.00216-2020.abstract N2 - Asthma is a major health problem all over the world [1]. Since SARS-COV-2 is a respiratory pathogen, it is important to quantify the risk that the current COVID-19 pandemic may represent for asthma patients.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Munoz reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, grants and personal fees from GlaxoSmithkline, grants from Menarini, personal fees from Novartis, personal fees from Teva, personal fees from Mundifarma, grants and personal fees from Chiesi, personal fees from Faes, outside the submitted work.Conflict of interest: Dr. Pilia has nothing to disclose.Conflict of interest: Dr. Ojanguren reports personal fees from GSK, personal fees from Astrazeneca, personal fees from Novatirs, personal fees from Boeheringuer_ingelheim, personal fees from Bial, personal fees from MSD, personal fees from Esteve, personal fees from Chiesi, grants and personal fees from Mundipharma, personal fees from TEVA, outside the submitted work.Conflict of interest: Dr. Romero-Mesones has nothing to disclose.Conflict of interest: Dr. Cruz has nothing to disclose. ER -